1. Atalay G, Cardoso F, Awada A, Piccart MJ (2003) Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 14: 1346–1363
2. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA (1991) Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 51: 144–149
3. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825–2831
4. Batova A, Kamps A, Gillies SD, Reisfeld RA, Yu AL (1999) The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res 5: 4259–4263
5. Beveridge RA, Miller JA, Kales AN, Binder RA, Robert NJ, Harvey JH, Windsor K, Gore I, Cantrell J, Thompson KA, Taylor WR, Barnes HM, Schiff SA, Shields JA, Cambareri RJ, Butler TP, Meister RJ, Feigert JM, Norgard MJ, Moraes MA, Helvie WW, Patton GA, Mundy LJ, Henry D, Mason B, Staddon A, Ford P, Katcher D, Houck W, Major WB, Gemma NW, Kay G, Priest E, Sowroy P, Bank B, Leibach S, Reisel H, Grad G, Warren RD, Ueno WM, Smith LF, Dobrzynski RF, Sheridan MJ (1998) A comparison of efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression. Cancer Invest 16: 366–373